Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-CD20/CD30 CAR-T in Relapsed/Refractory Lymphoma
NCT06532643Phase 1Recruiting
- Sponsor
- Shanghai First Song Therapeutics
- Start
- Aug 2023
- Primary completion
- Sep 2025
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of Anti-CD20/CD30-CAR-T cells in lymphoma, Hodgkin lymphoma (HL), diffuse large B-cell lymphoma (DLBCL) and 6 more, sponsored by Shanghai First Song Therapeutics. Primary endpoints: Safety and tolerance at 28 days and Manufacturing feasibility at 1 year. Started Aug 2023; status: recruiting.
02
Drugs
Anti-CD20/CD30-CAR-T cells
03
Conditions
lymphomaHodgkin lymphoma (HL)diffuse large B-cell lymphoma (DLBCL)primary mediastinal large B-cell lymphoma (PMBCL)follicular lymphoma, transformed (t-FL)
Beyond the preview
Go deeper on NCT06532643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06532643.